Literature DB >> 8555864

ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation.

G Y Lip1, G D Lowe.   

Abstract

Antithrombotic prophylaxis with long term warfarin or aspirin reduces thromboembolic risk in atrial fibrillation. Identification, risk assessment, and regular review of all patients with atrial fibrillation should be routine in general and hospital practice. Risk stratification is easily performed on clinical grounds--echocardiography may refine it.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8555864      PMCID： PMC2349725          DOI： 10.1136/bmj.312.7022.45

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


  2 in total

Review 1.  Does atrial fibrillation confer a hypercoagulable state?

Authors:  G Y Lip
Journal:  Lancet       Date:  1995-11-18       Impact factor: 79.321

Review 2.  Atrial fibrillation and stroke. Three new studies, three remaining questions.

Authors:  G W Albers
Journal:  Arch Intern Med       Date:  1994-07-11
  2 in total
  21 in total

1.  Massive thrombus originating from the interatrial septum and prolapsing into the left ventricle.

Authors:  A Avci; A Koç; D Köprülü; M Urkmez; E Alizade; G Acar; T Kırış
Journal:  Herz       Date:  2013-08-03       Impact factor: 1.443

2.  Summary of scientific evidence.

Authors: 
Journal:  Occas Pap R Coll Gen Pract       Date:  2002-02

3.  Doctors and patients must decide together whether anticoagulation is appropriate.

Authors:  A J Howitt
Journal:  BMJ       Date:  1998-07-18

4.  Accuracy and precision of the TAS analyser for near-patient INR testing by non-pathology staff in the community.

Authors:  P G Cachia; E McGregor; S Adlakha; P Davey; B M Goudie
Journal:  J Clin Pathol       Date:  1998-01       Impact factor: 3.411

5.  Hypercoagulability and haemodynamic abnormalities in atrial fibrillation.

Authors:  G Y Lip
Journal:  Heart       Date:  1997-05       Impact factor: 5.994

6.  Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages.

Authors:  Richard L Kravitz; Naihua Duan; Joel Braslow
Journal:  Milbank Q       Date:  2004       Impact factor: 4.911

7.  [Risk factors of a new cardio-embolic cerebral accident in non-valvular atrial fibrillation treated with acenocoumarol].

Authors:  E Vázquez Muñoz; J Gómez Cerezo; A Fernández Pavón
Journal:  Aten Primaria       Date:  2001-06-15       Impact factor: 1.137

Review 8.  Thyroid, hemostasis and thrombosis.

Authors:  F Marongiu; C Cauli; S Mariotti
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

9.  The risk stratification in atrial fibrillation.

Authors:  Domenico Prisco; Caterina Cenci; Elena Silvestri; Giacomo Emmi; Tommaso Barnini; Carlo Tamburini
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397

10.  How well does the target INR level maintain in warfarin-treated patients with non-valvular atrial fibrillation?

Authors:  Jun Hyung Kim; Young Bin Song; Dae Hee Shin; Je Sang Kim; Jin-Oh Choi; Young Kun On; June Soo Kim
Journal:  Yonsei Med J       Date:  2009-02-24       Impact factor: 2.759
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.